University of Maryland School of Medicine

The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients.

Fzata, Inc. has secured a clinical trial agreement with the NIH to sponsor a Phase 1 trial of FZ002, a genetically modified live yeast that expresses tetraspecific anti-toxins for C. difficile treatment.

The AURIGA trial demonstrated a significantly higher MRD-negative conversion rate at 12 months with daratumumab plus lenalidomide compared to lenalidomide alone (50.5% vs 10.8%).

Researchers report successful transplantation of 10-gene-edited pig hearts into baboons, achieving survival up to 225 days, demonstrating the potential for xenotransplantation.

Apremilast, an FDA-approved anti-inflammatory drug, significantly reduced alcohol intake in a clinical study of individuals with alcohol use disorder.

The National Institute of Allergy and Infectious Diseases (NIAID) has initiated a clinical trial where healthy adults will be deliberately infected with influenza virus under controlled conditions at four research sites across the US.